Diabetes Research and Clinical Practice
Volume 78, Issue 3, Supplement , Pages S23-S28 , 20 December 2007

Treatment of dyslipidemia in patients with type 2 diabetes: Overview and meta-analysis of randomized trials

  • Ivan Tkáč

      Affiliations

    • Corresponding Author InformationTel.: +421 55 615 2230; fax: +421 55 615 2249.

References 

  1. Turner RC, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). Br. Med. J. 1998;316:823–828
  2. Taskinen M-R. Diabetic dyslipidemia: from basic research to clinical practice. Diabetologia. 2003;46:733–749
  3. Tkáč I, Kimball BP, Lewis G, Uffelman K, Steiner G. The severity of coronary atherosclerosis in type 2 diabetes mellitus is related to the number of circulating triglyceride-rich lipoprotein particles. Arterioscler. Thromb. Vasc. Biol. 1997;17:3633–3638
  4. Shafrir E, Raz I. Diabetes: mellitus or lipidus?. Diabetologia. 2003;46:433–440
  5. Lehto S, Ronnemaa T, Haffner SM, Pyorala K, Kallio V, Laakso M. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes. 1997;46:1354–1359
  6. Howard BV, Robbins DC, Sievers ML, Lee ET, Rhoades D, Devereaux RB, et al. LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL. The Strong Heart Study. Arterioscler. Thromb. Vasc. Biol. 2000;20:830–835
  7. Austin MA, Breslow JL, Hennekens C, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and the risk of myocardial infarction. J. Am. Med. Assoc. 1998;260:1917–1921
  8. Molčányiová A, Stančáková A, Javorský M, Tkáč I. Beneficial effect of simvastatin treatment on LDL oxidation and antioxidant protection is more pronounced in combined hyperlipidemia than in hypercholesterolemia. Pharmacol. Res. 2006;54:203–207
  9. Haffner SM, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels. Arch. Intern. Med. 1999;159:2661–2667
  10. Keech A, et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose. Results from the LIPID trial. Diabetes Care. 2003;26:2713–2721
  11. Shepherd J, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–1630
  12. Serruys PWJC, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention. A randomized controlled trial. J. Am. Med. Assoc. 2002;287:3215–3222
  13. Heart Protection Study Collaborative Group. MR/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–2016
  14. Sever PJ, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149–1158
  15. Colhoun HH, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–696
  16. Knopp RH, D’Emden M, Smilde JG, Pocock SJ on behalf of the ASPEN Study Group. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes. The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN). Diabetes Care. 2006;29:1478–1485
  17. Wanner C, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 2005;353:238–248
  18. Shepherd J, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes. Diabetes Care. 2006;29:1220–1226
  19. Brijmohun RS, Hutten BA, Kastelein JJP, Stroes ESG. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds. J. Am. Coll. Cardiol. 2005;45:185–197
  20. Rubins HB, et al. Diabetes, plasma insulin, and cardiovascular disease. Subgroup analysis from the Department of Veteran Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch. Intern. Med. 2002;162:2597–2604
  21. The FIELD Study Investigators . Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD Study): randomised controlled trial. Lancet. 2005;366:1849–1861
  22. Grundy SM, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227–239
  23. Canadian Diabetes Association , Clinical Practice Guidelines Expert Committee . Dyslipidemia in adults with diabetes. Can. J. Diabetes. 2006;30:230–240
  24. Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ, et al. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis. 1994;106:241–253
  25. Barter PJ, Ballantyne CM, Carmena R, Castro Cabezas M, Chapman MJ, Couture P, et al. ApoB versus cholesterol to estimate cardiovascular risk and to guide therapy: report of the thirty-person ten-country panel. J. Intern. Med. 2006;259:247–258
  26. Waldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;358:2026–2033

PII: S0168-8227(07)00495-0

doi: 10.1016/j.diabres.2007.09.011

Diabetes Research and Clinical Practice
Volume 78, Issue 3, Supplement , Pages S23-S28 , 20 December 2007

Article Tools